Information Provided By:
Fly News Breaks for September 21, 2016
CLVS
Sep 21, 2016 | 07:22 EDT
Stifel analyst Thomas Shrader wrote that several events in the last few weeks have significantly reduced the risk facing Clovis. Among these events are the FDA's acceptance of the new drug application for Clovis' PARP inhibitor, rucaparib and negative data for a competing drug, Olaparib. The analyst says that "acquisition rumors are swirling around" the developers of PARP inhibitors. He keeps a Buy rating on Clovis.
News For CLVS From the Last 2 Days
There are no results for your query CLVS